# Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants

> **NCT05863442** · PHASE1 · UNKNOWN · sponsor: **Turgut Ardika PTY LTD** · enrollment: 120 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Soliris 300 MG in 30 ML Injection
- **DRUG:** TUR03 300 MG in 30 ML Injection

## Key facts

- **NCT ID:** NCT05863442
- **Lead sponsor:** Turgut Ardika PTY LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-10
- **Primary completion:** 2024-07-23
- **Final completion:** 2024-10-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05863442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05863442, "Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05863442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*